Analyzing...
Loading company...
Poly Medicure Ltd. engages in the provision and sales of medical devices. The company is headquartered in Faridabad, Haryana. The company went IPO on 2011-12-05. The firm is primarily in the business of manufacture and sale of medical devices. The firm offers a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, covid care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. The company supplies its products to approximately 120 countries, in Europe, Africa, Americas, Australia, and Asia. Its products include suction control valve, safety arterial cannula, VTM Kit, VLTM kit, blood collection needle with flashback, and pre-filled syringes. The firm operate nine manufacturing facilities across India, China, Egypt, and Italy. In India, it operates six manufacturing facilities, four of which are situated at Faridabad (Haryana), and one each in Jaipur (Rajasthan) and Haridwar (Uttarakhand).
No significant concerns identified
Nothing flagged for monitoring
“Operates in Healthcare — Equipment & Devices.”
₹1,875 Cr revenue.
COGS 31.8%, employees 21.5%.
“domestic business should probably grow around 20 to 25%, and international international business should grow around 20 to 15%.”
“guidance is between 9% to 10%.”
“domestic business overall should grow around 25% for next year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 10.4%▲ | 8.6% |
| ROCE | 13.2%▲ | 12.6% |
| Net Margin | 16.1%▲ | 8.2% |
| EBITDA Margin | 27.8%▲ | 15.6% |
| Debt To Equity | 0.11x | 0.11x |
| Rev Growth 3yr | 20.1%▲ | 14.8% |
| EPS Growth 3yr | 19.4%▲ | 8.4% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,875 Cr +12.3% | ₹1,670 Cr +21.4% | ₹1,376 Cr +23.4% | ₹1,115 Cr +20.8% | ₹923 Cr +17.4% | ₹786 Cr +14.4% | ₹687 Cr +12.5% | ₹611 Cr |
| Other Income | ₹120 Cr +34.3% | ₹89 Cr +51.7% | ₹59 Cr +62.4% | ₹36 Cr -4.5% | ₹38 Cr +105.8% | ₹18 Cr -0.3% | ₹18 Cr +1.1% | ₹18 Cr |
| Total Income | ₹1,995 Cr +13.4% | ₹1,759 Cr +22.6% | ₹1,435 Cr +24.6% | ₹1,151 Cr +19.8% | ₹961 Cr +19.4% | ₹805 Cr +14.1% | ₹706 Cr +12.2% | ₹629 Cr |
| COGS | ₹597 Cr +7.6% | ₹555 Cr +14.9% | ₹483 Cr +18.9% | ₹406 Cr +16.6% | ₹348 Cr +32.9% | ₹262 Cr +20.6% | ₹217 Cr +4.0% | ₹209 Cr |
| ₹1,566 Cr +19.4% | ₹1,312 Cr +20.0% | ₹1,093 Cr +19.3% | ₹916 Cr +19.2% | ₹768 Cr +22.3% | ₹628 Cr +7.9% | ₹582 Cr +9.7% | ₹530 Cr | |
| Profit Before Tax | ₹422 Cr -5.7% | ₹447 Cr +30.9% | ₹342 Cr +45.1% | ₹236 Cr +22.2% | ₹193 Cr +9.1% | ₹177 Cr +43.0% | ₹124 Cr +23.5% | ₹100 Cr |
| Exceptional Items | (₹7 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹1 Cr |
| ₹107 Cr -6.3% | ₹114 Cr +32.5% | ₹86 Cr +47.8% | ₹58 Cr +19.4% | ₹49 Cr +10.3% | ₹44 Cr +48.0% | ₹30 Cr -13.9% | ₹35 Cr | |
| Net Profit | ₹321 Cr -5.3% | ₹339 Cr +31.1% | ₹258 Cr +44.1% | ₹179 Cr +22.4% | ₹147 Cr +7.8% | ₹136 Cr +41.7% | ₹96 Cr +46.6% | ₹65 Cr |
| Profit (Owners) | ₹322 Cr -4.8% | ₹339 Cr +31.1% | ₹258 Cr +44.1% | ₹179 Cr +22.4% | ₹147 Cr +7.8% | ₹136 Cr +41.7% | ₹96 Cr +46.6% | ₹65 Cr |
| Minority Interest | (₹1 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹46 Cr ↑ Recovery | (₹1 Cr) -53.3% | (₹0.88 Cr) ↓ Decline | ₹0.41 Cr +71.3% | ₹0.24 Cr +126.7% | ₹0.10 Cr -63.4% | ₹0.29 Cr | ₹0.02 Cr |
| EPS | ₹31.79 | ₹33.41 | ₹26.91 | ₹18.69 | ₹15.28 | ₹14.17 | ₹10.86 | ₹7.41 |
| Diluted Shares | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹9 Cr |
| Profit Or Loss Of Associates | ₹6 Cr +9.7% | ₹5 Cr +105.0% | ₹3 Cr +31.1% | ₹2 Cr -21.3% | ₹2 Cr -26.1% | ₹3 Cr +54.7% | ₹2 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Poly Medicure Limited has informed the Exchange about Certificate Regulation 74(5) under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.
Poly Medicure Limited has informed the Exchange about Update in relation to the proceedings before the Hon''ble Delhi High Court regarding stamp duty matter
Poly Medicure Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Poly Medicure Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulati...
Poly Medicure Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulati...
Poly Medicure Limited has informed the Exchange about Investor/Analyst Meet
Poly Medicure Limited has informed the Exchange about Investors/Analysts Meet Schedule
Poly Medicure Limited has informed the Exchange about Transcript
Poly Medicure Limited has informed that Investors Call Scheduled To Be Held On 27 May, 2026 Is Cancelled - Updates On Call
Poly Medicure Limited has informed the Exchange about Copy of Newspaper Publication for the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026
Poly Medicure Limited has informed the Exchange about Investor Presentation
Poly Medicure Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 3.50 per equity share.
Poly Medicure Limited has submitted to the Exchange, the Audited financial results(Standalone & Consolidated) for the quarter and year ended March 31, 2026.
Poly Medicure Limited has informed the Exchange about Grant Of Stock Options- Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Intimation of Investors/Analysts Call for the Audited Financial Results for the quarter and year ended 31st March, 2026.